Immunomic Therapeutics

118 articles about Immunomic Therapeutics

• Immunomic Delivering Closing Keynote Address At Wharton DC Innovation Summit

  4/25/2016

• Immunomic And Lysosomal Associated Membrane Protein (LAMP) Based Nucleic Acid Immunotherapy Featured At 2016 World Vaccine Congress

  3/29/2016

• MEDIA INVITED: Immunomic, Talks Vital Vaccine Technology Advancement At Biotech Showcase 2016

  1/13/2016

• Astellas, Immunomic Forge $300 Million+ LAMP-vax Pact

  10/9/2015

• Immunomic Therapeutics To Present At Skin Vaccination Summit In Switzerland

  8/28/2015

• Immunomic Therapeutics Taps Micronaut To Visually Demonstrate Its LAMP-Vax Programs

  6/16/2015

• Immunomic Therapeutics Names Louise Peltier As Vice President, Regulatory Affairs

  5/6/2015

• Immunomic Therapeutics Appoints Eric Winzer As Chief Financial Officer

  5/4/2015

• Immunomic Therapeutics Awarded SBIR Grant From NIH For Nanoplasmid Peanut Allergy Vaccine Development

  3/31/2015

• Immunomic Therapeutics Receives Positive Feedback From FDA Following Pre-IND Discussions for Its Proprietary Peanut Allergy Vaccine

  3/25/2015

• Immunomic Therapeutics To Present At BIO-Europe Annual Conference

  3/9/2015

• Immunomic Therapeutics Explains Proprietary LAMP-vax Platform In Nature Advertorial Supplement

  3/4/2015

• Immunomic Therapeutics To Present Data On Its Proprietary LAMP Vaccine Platform At 2015 American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting

  2/20/2015

• Astellas Pharma Inc.. Immunomic Therapeutics Forge $70 Million Vaccine Pact

  1/30/2015

• Immunomic Therapeutics Closes $3 Million Debt Pre-Series B Round

  7/17/2013

• Myriad Genetics, Inc. Supreme Court Case Has Promising Outcome for Immunomic Therapeutics

  6/20/2013

• Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy

  4/25/2013

• Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study

  11/8/2012